
HYDROCORTISONE- hydrocortisone tablet Greenstone LLC

Hydrocortisone tablets, USP

DESCRIPTION

Hydrocortisone tablets contain hydrocortisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Hydrocortisone USP is white to practically white, odorless, crystalline powder with a melting point of about 215° C. It is very slightly soluble in water and in ether; sparingly soluble in acetone and in alcohol; slightly soluble in chloroform.

The chemical name for hydrocortisone is pregn-4-ene-3,20-dione,11,17,21-trihydroxy-, (11β) -. Its molecular weight is 362.46 and the structural formula is as outlined below.



Hydrocortisone tablets are available for oral administration in three strengths: each tablet contains either 5 mg, 10 mg, or 20 mg of hydrocortisone. Inactive ingredients: calcium stearate, corn starch, lactose, mineral oil, sorbic acid, sucrose.

ACTIONS

Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have saltretaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

INDICATIONS AND USAGE

Hydrocortisone tablets are indicated in the following conditions.

1. Endocrine Disorders

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer

2. Rheumatic Disorders

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis

3. Collagen Diseases

During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis

4. Dermatologic Diseases

Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis

5. Allergic States

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions

6. Ophthalmic Diseases

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia

7. Respiratory Diseases

Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis

8. Hematologic Disorders

Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia

9. Neoplastic Diseases

For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood

10. Edematous States

To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

11. Gastrointestinal Diseases

To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis

12. Miscellaneous

Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

CONTRAINDICATIONS

Systemic fungal infections and known hypersensitivity to components

WARNINGS

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function.¹

These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.² There may be decreased resistance and inability to localize infection when corticosteroids are used.

Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

Usage in pregnancy

Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.

Corticosteroids have been shown to impair fertility in male rats.

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.

The use of hydrocortisone tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.

If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

PRECAUTIONS

General Precautions

Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid

therapy. Discontinuation of corticosteroids may result in clinical remission.

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. In patients with suspected pheochromocytoma, consider the risk of pheochromocytoma crisis prior to administering corticosteroids.

In post marketing experience tumor lysis syndrome (TLS) has been reported in patients with malignancies, including hematological malignancies and solid tumors, following the use of systemic corticosteroids alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with tumors that have a high proliferative rate, high tumor burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precautions should be taken.

Drug Interactions

The pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

Information for the Patient

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.

ADVERSE REACTIONS

Fluid and Electrolyte Disturbances

Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension

Musculoskeletal

Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones

Gastrointestinal

Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.

Dermatologic

Impaired wound healing Thin fragile skin Petechiae and ecchymoses Facial erythema Increased sweating May suppress reactions to skin tests

Neurological

Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Convulsions Vertigo Headache Epidural lipomatosis

Endocrine

Development of Cushingoid state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness Menstrual irregularities Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics

Ophthalmic

Central serous chorioretinopathy Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos

Metabolic

Negative nitrogen balance due to protein catabolism

Blood and lymphatic system disorders

Leukocytosis

DOSAGE AND ADMINISTRATION

The initial dosage of hydrocortisone tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, hydrocortisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of hydrocortisone for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually, rather than abruptly.

HOW SUPPLIED

Hydrocortisone tablets are available in the following strengths and package sizes:

5 mg (white, round, scored, imprinted CORTEF 5) Bottles of 50 NDC 59762-0073-1

10 mg (white, round, scored, imprinted CORTEF 10) Bottles of 100 NDC 5976220 mg (white, round, scored, imprinted CORTEF 20) Bottles of 100 NDC 59762-0075-1

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

REFERENCES

- Fekety R. Infections associated with corticosteroids and immunosuppressive therapy. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. *Infectious Diseases.* Philadelphia: WB Saunders Company 1992:1050–1.
- Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. *Rev Infect Dis* 1989:11(6):954–63.

This product's label may have been updated. For current full prescribing information please visit www.greenstonellc.com

GREENSTONE® BRAND Distributed by: Greenstone LLC Morgantown, WV 26505 U.S.A.

LAB-0634-4.0 Revised December 2023

PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label


NDC 59762-0073-1 50 Tablets

GREENSTONE[®] BRAND

hydrocortisone tablets, USP

5 mg

Rx only



PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label


NDC 59762-0074-1 100 Tablets

GREENSTONE[®] BRAND

hydrocortisone tablets, USP

10 mg

Rx only



PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label


NDC 59762-0075-1 100 Tablets

GREENSTONE[®] BRAND

hydrocortisone tablets, USP

20 mg

Rx only



hydrocortisone t	ablet						
Product Info	rmation						
Product Type		HUMAN PRESCRIPTION DR	RUG	Item Code	e (Source)	NDC:59	762-0073
Route of Admin	istration	ORAL					
Active Ingred	ient/Active	Moiety					
	•	edient Name			Basis of S	trength	Strength
HYDROCORTISON	IE (UNII: W4X0X	7BPJ) (HYDROCORTISONE -	- UNII:WI42	X0X7BPJ)	HYDROCORTI	SONE	5 mg
Inactive Ingre	edients						
		Ingredient Name				Str	ength
CALCIUM STEARA							
STARCH, CORN (L		J)					
		UNII: J2B2A4N98G)					
MINERAL OIL (UNI	I: T5L8T28FGP)	UNII: J2B2A4N98G)					
MINERAL OIL (UNI SORBIC ACID (UN	I: T5L8T28FGP) II: X045WJ989B)	UNII: J2B2A4N98G)					
LACTOSE, UNSPE MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C	I: T5L8T28FGP) II: X045WJ989B)	(UNII: J2B2A4N98G)					
MINERAL OIL (UNI SORBIC ACID (UN	I: T5L8T28FGP) II: X045WJ989B)	(UNII: J2B2A4N98G)					
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C	I: T5L8T28FGP) II: X045WJ989B) 151H8M554)	(UNII: J2B2A4N98G)					
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char	I: T5L8T28FGP) II: X045WJ989B) 151H8M554)	(UNII: J2B2A4N98G)	Score	2		2 pieces	
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color	I: T5L8T28FGP) II: X045WJ989B) 151H8M554) acteristics		Score Size	3		2 pieces 8mm	
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color Shape	I: T5L8T28FGP) II: X045W989B) 151H8M554) acteristics WHITE		Size	e nt Code			
MINERAL OIL (UNI SORBIC ACID (UN	I: T5L8T28FGP) II: X045W989B) 151H8M554) acteristics WHITE		Size			8mm	
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color Shape Flavor	I: T5L8T28FGP) II: X045W989B) 151H8M554) acteristics WHITE		Size			8mm	
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color Shape Flavor Contains	I: T5L8T28FGP) II: X045W989B) 151H8M554) acteristics WHITE		Size			8mm	
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color Shape Flavor Contains Packaging	I: T5L8T28FGP) II: X045WJ989B) 151H8M554) acteristics WHITE ROUND (h		Size			8mm CORTEF; Market	
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color Shape Flavor Contains Packaging	I: T5L8T28FGP) II: X045WJ989B) 151H8M554) acteristics WHITE ROUND (h	alf oval)	Size Imprin	nt Code Marketii		8mm CORTEF; Market	5 ting End
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color Shape Flavor Contains Packaging # Item Code	I: T5L8T28FGP) II: X045WJ989B) 151H8M554) acteristics WHITE ROUND (h	alf oval) ckage Description	Size Imprin	nt Code Marketii Da		8mm CORTEF; Market	5 ting End
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color Shape Flavor Contains Packaging # Item Code 1 NDC:59762- 0073-1	I: T5L8T28FGP) I: X045WJ989B) 151H8M554) acteristics WHITE ROUND (h 7000000000000000000000000000000000000	alf oval) ckage Description E; Type 0: Not a Combinat	Size Imprin	nt Code Marketii Da		8mm CORTEF; Market	5 ting End
MINERAL OIL (UNI SORBIC ACID (UNI SUCROSE (UNII: C Product Char Color Shape Flavor Contains Packaging # Item Code	I: T5L8T28FGP) I: X045WJ989B) 151H8M554) acteristics WHITE ROUND (h Pac 50 in 1 BOTTL Product	alf oval) ckage Description E; Type 0: Not a Combinat	Size Imprin	nt Code Marketin Da 02/20/2013 Marke		8mm CORTEF; Market Da	5 ting End

HYDROCORTISONE

Pr	oduct Infor	mation						
Pr	oduct Type		HUMAN PRESCRIPTIO	N DRUG	Item Cod	e (Source)	NDC:59	9762-0074
	ute of Admin	istration	ORAL			. ,		
40	tive Ingred	ient/Active	Moiety					
	Ingredient Name Basis of S						trength	Strengt
ΗY	DROCORTISON	E (UNII: W4X0X)	'BPJ) (HYDROCORTISO	NE - UNII:WI	4X0X7BPJ)	HYDROCORTIS	SONE	10 mg
n	active Ingre	dients						
			Ingredient Nam	e			Str	rength
	ARCH, CORN (U							
	NERAL OIL (UNII		UNII: J2B2A4N98G)					
***	NERAL OIL (UNII	: ISLOIZOFGP)						
ŝ	PRIC ACID (LINI							
	RBIC ACID (UNI CROSE (UNII: CI	-						
SU	CROSE (UNII: CI	L51H8M554)						
su Pr		L51H8M554)		Score			2 pieces	
su Pr Co	CROSE (UNII: CI Oduct Chara Ior	acteristics WHITE	lf oval)	Score			2 pieces 9mm	
su Pr Co Sh	CROSE (UNII: CI	acteristics	lf oval)	Size	nt Code		-	0
SU Pr Co Sh Fla	CROSE (UNII: CI roduct Chara lor ape	acteristics WHITE	lf oval)	Size	nt Code		9mm)
SU Pr Co Sh Fla	crose (UNII: CI roduct Chara lor ape ivor	acteristics WHITE	lf oval)	Size	nt Code		9mm)
SU Pr Co Sh Fla Co	crose (UNII: CI roduct Chara lor ape ivor	acteristics WHITE	lf oval)	Size			9mm CORTEF;10	
SU Pr Co Sh Fla Co	CROSE (UNII: CI roduct Chara lor ape ivor ntains	Acteristics WHITE ROUND (ha	lf oval) : kage Descriptio	Size Imprir	Marketi		9mm CORTEF;10 Marke t) ting End ate
SU Pr Co Sh Fla Co Pa #	crose (UNII: Cl oduct Chara lor ape ovor ntains	Acteristics WHITE ROUND (ha		Size Imprin	Marketi	ng Start	9mm CORTEF;10 Marke t	ting End
SU Pr Co Sh Fla Co Pa #	crose (UNII: C1 oduct Chara lor ape ovor ntains ckaging Item Code NDC:59762-	Acteristics WHITE ROUND (ha	kage Description	Size Imprin	Marketi Da	ng Start	9mm CORTEF;10 Marke t	ting End
Pr Co Sh Fla Co Pa	crose (UNII: C1 oduct Chara lor ape ovor ntains ckaging Item Code NDC:59762-	Acteristics WHITE ROUND (hat 100 in 1 BOTT Product	: kage Descriptio LE; Type 0: Not a Com	Size Imprin	Marketi Da	ng Start	9mm CORTEF;10 Marke t	ting End
Pr Co Sh Fla Co Pa #	CROSE (UNII: C1 roduct Chara lor ape tvor ntains ckaging Item Code NDC:59762- 0074-1	Acteristics WHITE ROUND (ha 100 in 1 BOTT Product	: kage Descriptio LE; Type 0: Not a Com	Size Imprin	Marketi Da 02/20/2013 Marke	ng Start	9mm CORTEF;10 Market Da	ting End

HYDROCORTISONE

hydrocortisone tablet

Product Information

Product Type		HUMAN PRESCRIPTION D	DUG	item Cod	e (Source)	NDC:55	9762-0075
Route of Admin	istration	ORAL					
Active Ingred	ient/Active	Moiety					
	Ing	redient Name			Basis of S	trength	Strengt
HYDROCORTISON	E (UNII: W4X0)	(7BPJ) (HYDROCORTISONE	- UNII:W4	1X0X7BPJ)	HYDROCORTI	SONE	20 mg
Inactive Ingre	dients						
		Ingredient Name				Sti	rength
CALCIUM STEARA	TE (UNII: 776X	M7047L)					
STARCH, CORN (U	NII: 08232NY3	SJ)					
ACTOSE, UNSPE	CIFIED FORM	(UNII: J2B2A4N98G)					
MINERAL OIL (UNII	: T5L8T28FGP)						
SORBIC ACID (UNI	I: X045WJ989B)						
SUCROSE (UNII: CI	L51H8M554)						
Product Chara	acteristics						
Color	WHITE		Score			2 pieces	
Shape	ROUND (h	alf oval)	Size			10mm	
Flavor			Imprin	nt Code		CORTEF;20)
Contains							
Packaging							
# Item Code	Pa	ckage Description		D .	ing Start ate	–	ting End ate
NDC:59762- 0075-1	100 in 1 BOT Product	TLE; Type 0: Not a Combir	nation	02/20/2013			
Marketing	Information	tion					
Marketing Category	Applic	ation Number or Mon Citation	nograph		eting Start Date		eting End Date
NDA AUTHORIZED	NDA0086	97		02/20/20)13		
GENERIC							

Labeler - Greenstone LLC (825560733)

Registrant - Pfizer Inc (113480771)